Pubblicazioni

Pubblicazioni

2020

LE TEMPISTICHE AUTORIZZATIVE DI AIFA: UN CONFRONTO TRA LE DUE COMMISSIONI CONSULTIVE E TECNICO-SCIENTIFICHE SUCCEDUTESI NEL PERIODO 2015-2020

Glob Reg Health Technol Assess 2020; 7(1): 109-114 DOI: 10.33393/grhta.2020.2173

Raimondo P., Casilli G., Isernia M., Lidonnici D., Ravasio R., Ronco V., Lanati E.P.

PERCUTANEOUS CRYOABLATION VS SOC IN SMALL KIDNEY CANCERS: THE ITALIAN EXPERIENCE

Minerva Urol Nefrol. 2020 Feb 19. doi: 10.23736/S0393-2249.20.03625-5.

Celia A, Pusceddu C, Silvestri T, Gidaro GB, Iannello F, Lanati EP, D'ausilio A.

THE BURDEN OF ATOPIC DERMATITIS IN ADULTS IN ITALY

G Ital Dermatol Venereol. 2020 Feb;155(1):19-23. doi: 10.23736/S0392-0488.19.06430-7. Epub 2019 Sep 12.

Sciattella P, Pellacani G, Pigatto PD, Patrizi A, Peris K, Calzavara-Pinton P, Girolomoni G, Lanati EP, D'ausilio A, Mennini FS.

2019

PERSISTENCE ON APIXABAN IN ATRIAL FIBRILLATION PATIENTS: A RETROSPECTIVE MULTICENTRE STUDY

J Cardiovasc Med (Hagerstown). 2019 Feb;20(2):66-73.

Verdecchia P, D'Onofrio A, Russo V, Fedele F, Adamo F, Benedetti G, Ferrante F, Lodigiani C, Paciullo F, Aita A, Bartolini C, Molini MG, Di Lenarda A, Mazzone C, Scotti L, Lanati EP, Iorio A.

POSITIVE IMPACT OF INNOVATIVE STATUS IN P&R PROCESS TIMING IN ITALY

Poster PMU46, ISPOR Europe 2019, Copenhagen, Denmark, Value Health. 2019 Nov;22(S3): S716

Enrici A, Lidonnici D, Isernia M, Lanati EP.

PRICE ANALYSIS OF NEW MEDICINAL PRODUCTS REIMBURSED IN ITALY AND GERMANY

Poster PMU65, ISPOR Europe 2019, Copenhagen, Denmark, Value Health. 2019 Nov;22(S3): S719

Casilli G, Lidonnici D, Isernia M, Morichi M, Konstanski M, Kuchenbecker U, Mittendorf T, Lanati EP.

X-LINKED HYPOPHOSPHATEMIC RICKETS: AN ITALIAN EXPERTS’ OPINION SURVEY X-LINKED HYPOPHOSPHATEMIC RICKETS: AN ITALIAN EXPERTS’ OPINION SURVEY

Emma et al. Italian Journal of Pediatrics (2019) 45:67

Emma F., Cappa M., Antoniazzi F., Bianchi M. L., Chiodini I., Eller Vainicher C., Di Iorgi N., Maghnie M., Cassio A., Balsamo A., Baronio F., de Sanctis L., Tessaris D., Baroncelli G. I., Mora S., Brandi M. L., Weber G., D’Ausilio A. and Lanati EP

FIFTY SHADES OF... INNOVATIVENESS IN ITALY

Poster PMU44, ISPOR Europe 2019, Copenhagen, Denmark, Value Health. 2019 Nov;22(S3): S715–S716.

Casilli G, Ronco V, Lidonnici D, Lanati EP.

PREVALENCE VS. TREATMENT COST: ANALYSIS OF DRUGS FOR RARE DISEASE IN ITALY

Poster PMU45, ISPOR Europe 2019, Copenhagen, Denmark, Value Health. 2019 Nov;22(S3): S716

Casilli G, Lidonnici D, Morichi M, Isernia M, Lanati EP.

NEGOTIATION OUTCOMES IN ITALY: WHAT’S THE IMPACT OF ORPHAN DRUG DESIGNATION?

Poster PMU49, ISPOR Europe 2019, Copenhagen, Denmark, Value Health. 2019 Nov;22(S3): S716–S717.

Enrici A, Lidonnici D, Lanati EP.

ORPHAN DRUG DESIGNATION: NO IMPACT ON P&R PROCESS TIMING IN ITALY

Poster PMU47, ISPOR Europe 2019, Copenhagen, Denmark, Value Health. 2019 Nov;22(S3): S716

Enrici A, Lidonnici D, Isernia M, Lanati EP.

P&R PROCESS IN ITALY: A FOCUS ON NEGOTIATION OUTCOMES OF INNOVATIVE DRUGS

Poster PMU48, ISPOR Europe 2019, Copenhagen, Denmark, Value Health. 2019 Nov;22(S3): S716

Enrici A, Lidonnici D, Lanati EP.

2018

ANALYSIS OF APPROVAL TIMING FOR 89 NEW DRUGS IN ITALY FROM JANUARY 2015 TO MAY 2018

Journal: Value Health. 2018 October;21(S3): S163. Poster PHP76, ISPOR Europe 2018, Barcelona, Spain

Lidonnici D, Lanati EP, Niedecker S, Isernia M.

OUTCOME OF NEW DRUG NEGOTIATION PROCESS IN ITALY: APPROVAL CONDITIONS (2015-2018)

Journal: Value Health. 2018 October;21(S3): S1. Oral presentation AC1, ISPOR Europe 2018, Barcelona, Spain

Lidonnici D, Lanati EP, Niedecker S, Isernia M, Ronco V.

ECONOMIC AND ORGANIZATIONAL IMPACT OF A VASCULAR ACCESS TEAM IN AN ITALIAN HOSPITAL

Journal: Value Health. 2018 October;21(S3): S315. Poster PMU42, ISPOR Europe 2018, Barcelona, Spain

Lanati EP, Isernia A, Orlando VL.

PRESSURE INJURIES IN PATIENTS WITH URINARY INCONTINENCE: EFFICACY OF REGENERA, A NEW MEDICAL DEVICE TESTED AT THE OSPEDALE MAGGIORE IN NOVARA

Journal: Value Health. 2018 October;21(S3): S246. Poster PMD21, ISPOR Europe 2018, Barcelona, Spain 

Iorio A, Arreni A, Bottosso S, Lanati EP.

EARLY ACCESS PROGRAMS: AN ANALYSIS SINCE THEIR ESTABLISHMENT IN ITALY

Journal: Value Health. 2018 October;21(S3): S159–S160. Poster PHP56, ISPOR Europe 2018, Barcelona, Spain

D'Ausilio A, Seyed Khoei N, Lanati EP

STATE OF THE ART AND FUTURE PERSPECTIVES OF ADVANCED THERAPY MEDICINAL PRODUCTS IN ITALY AND IN THE INTERNATIONAL ARENA

Journal: Value Health. 2018 May;21(S1): S92. Poster PHP31

Lidonnici D, Ronco V, Niedecker S, D'Ausilio A, Lanati EP.

UPDATED NEW DRUGS APPROVAL TIMING IN ITALY (2015-2017)

Journal: Value Health. 2018 May;21(S1): S91-92. Poster PHP27  

Lidonnici D, Lanati EP, Niedecker S, Isernia M.

NEW DRUGS APPROVAL IN ITALY: UPDATED ANALYSIS OF THE APPLIED NEGOTIATION CONDITIONS 2015-2017

Journal: Value Health. 2018 May;21(S1): S92.  Poster PHP28

Lidonnici D, Lanati EP, Niedecker S, Isernia M.

INCONTINENZA URINARIA E LESIONI CUTANEE, L'ESPERIENZA REGENERA

Journal: www.nurse24.it, Maggio 2018

Iorio A, Arreni A, Bottosso S, Lanati EP.

TEMPI DI ACCESSO AI FARMACI IN ITALIA NEL PERIODO 2015-2017: ANALISI DELLE TEMPISTICHE DI VALUTAZIONE DELL’AGENZIA ITALIANA DEL FARMACO

Journal: Global & Regional Health Technology Assessment Volume 2018: 1–9, August 2, 2018

Lidonnici D, Ronco V, Isernia M, Lanati EP, Jommi C, Canonico PL, Genazzani A. 

ANALISI DI BUDGET IMPACT SU MODELLI DI ACQUISTO E GESTIONE DEGLI AUSILI PER L’INCONTINENZA URINARIA A CONFRONTO

Journal: Global & Regional Health Technology Assessment Volume XX: 1–10, April 9, 2018

Mennini FS, Pisanti P, Terzoni S, Lanati EP, Marcellusi A, Marcelli A, Iorio A.

EPIDEMIOLOGIA DEL MIELOMA MULTIPLO E CARATTERISTICHE CLINICHE DEI PAZIENTI

Journal: Giornale Italiano di Farmacoeconomia e Farmacoutilizzazione 2018; 10 (2): 23-30, giugno 2018

Scotti L,Montefusco V, Lanati EP, Orlando VL, Iorio A,Verdini V.

ANALISI DI IMPATTO SUL BUDGET DI DIFFERENTI ANALOGHI AD AZIONE RAPIDA DELL’INSULINA IN ITALIA

Journal: GRHTA 1-6, April 5, 2018 GRHTA 1-6, April 5, 2018

Lanati EP, La Malfa P, Iorio A, Mennini FS,Fanelli F, Gentile S.

2017

FROM OFF-LABEL TO REPURPOSED DRUG IN NON-ONCOLOGICAL RARE DISEASES: DEFINITION AND STATE OF THE ART IN SELECTED EU COUNTRIES

Journal: Med Access @ point care 2017; 1(1): e87 - e97

Minghetti P, Lanati E.P, Godfrey J, Solà-Morales O, Wong O, Selletti S

THE COST OF BREAST CANCER ADJUVANT CHEMOTHERAPY IN A DISTRICT OF LOMBARDY, ITALY

Journal: Clinico Economics, Vol 13 Anno 2018, Pag 11-22

Sgarella A, Riboni G, Ferrari A, Grasso D, Ferraris E, Lanati EP, Iorio A

REAL-WORLD EVIDENCE ON CLINICAL USE OF A NOVEL ORAL ANTICOAGULANT FOR THE TREATMENT OF ATRIAL FIBRILLATION

Journal: Value Health 20 (2017), A625; Poster PCV134, Glasgow, ISPOR 20th Annual European Congress 2017

Verdecchia P, Lanati E.P, Verdini V, Corrao G, Scotti L, Airoldi C, Iorio A.

PRIMARY BILIARY CHOLANGITIS: ADVANCES IN MANAGEMENT AND TREATMENT OF THE DISEASE

Journal: Dig Liver Dis. 2017 May;S1590-8658(17)30857-5

Invernizzi P, Floreani A, Carbone M, Marzioni M, Craxi A, Muratori L, Vespasiani Gentilucci U, Gardini I, Gasbarrini A, Kruger P, Mennini FS, Ronco V, Lanati EP, Canonico PL, Alvaro D

REAL-WORLD EVIDENCE ON SAFETY AND EFFECTIVENESS OF A NOVEL ORAL ANTICOAGULANT FOR THE TREATMENT OF ATRIAL FIBRILLATION: A RETROSPECTIVE ANALYSIS IN FIVE ITALIAN DISTRICTS

Poster, 38° National Congress Italian Society of Interventional Cardiology. 10-13 Ottobre 2017.

Verdecchia P, D’Onofrio A, Russo V, Fedele F,  Adamo F,  Benedetti G, Ferrante F, Lodigiani C, Paciullo F, Di Lenarda A, Mazzone C, Scotti L, Iorio A.

PERSISTENCE AND DISCONTINUATION OF APIXABAN AMONG PATIENTS WITH ATRIAL FIBRILLATION: A RETROSPECTIVE ANALYSIS IN FIVE ITALIAN DISTRICTS

Poster, IX Congresso Nazionale SISMEC, La statistica a supporto della salute: dalla prevenzione alla continuità delle cure, Gargnano, 13-14-15-16 Settembre 2017

Verdecchia P, Lanati EP,  Verdini V, Corrao G, Scotti L, Airoldi C, Iorio A

REAL-LIFE SAFETY AND EFFECTIVENESS OF APIXABAN IN PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION

Poster, 38° Congresso Nazionale della Società Italiana di Farmacologia.  Rimini, 25-28 Ottobre 2017.

Verdecchia P, Lanati E.P, Verdini V, Corrao G, Scotti L, Airoldi C, Iorio A.

NEW DRUGS APPROVAL IN ITALY: ANALYSIS OF THE APPLIED NEGOTIATION CONDITIONS 2015-2017

Poster PHP45, Glasgow, ISPOR 20th Annual European Congress 2017

Lidonnici D, Lanati E.P, Isernia M.

NEW DRUGS APPROVAL TIMING IN ITALY (2015-2017)

Poster PHP46, Glasgow, ISPOR 20th Annual European Congress 2017

Lidonnici D, Lanati E.P, Isernia M.

COST EFFECTIVENESS ANALYSIS OF THE USE OF ENSTILAR® COMPARED TO DOVOBET® GEL IN THE TREATMENT OF PSORIASIS IN ITALY

Poster PSS19, Glasgow, ISPOR 20th Annual European Congress 2017

Orlando V.L, Lanati E.P.

BUDGET IMPACT ANALYSIS OF ENSTILAR® FOR THE TREATMENT OF PSORIASIS IN ITALY

Poster PSS9, Glasgow, ISPOR 20th Annual European Congress 2017

Orlando V.L, Lanati E.P.

RETROSPECTIVE STUDY ON ITALIAN ADPKD DISEASE MANAGEMENT COST (REINA)

Poster PUK8, Glasgow, ISPOR 20th Annual European Congress 2017

Lanati E.P, Iorio A, Marcelli A, Ruggeri M, Rolli F.R, Caramuscio R, Ballantini F, Scolari F

RETROSPECTIVE STUDY ON ITALIAN ADPKD DISEASE MANAGEMENT COST (REINA)

Poster, 38° Congresso Nazionale della Società Italiana di Farmacologia.  Rimini, 25-28 Ottobre 2017.

Lanati E.P, Iorio A, Marcelli A, Ruggeri M, Romana Rolli F, Caramuscio R, Ballantini F, Scolari F.

RETROSPECTIVE STUDY ON ITALIAN ADPKD DISEASE MANAGEMENT COST (REINA)

Poster, IX Congresso Nazionale SISMEC, La statistica a supporto della salute: dalla prevenzione alla continuità delle cure, Gargnano, 13-14-15-16 Settembre 2017

Lanati E.P,  Iorio A, Marcelli A,  Ruggeri M, Rolli F.R,  Caramuscio R, Ballantini F,  Scolari F

2016

HCV - ESTIMATION OF THE NUMBER OF DIAGNOSED PATIENTS ELIGIBLE TO THE NEW ANTI-HCV THERAPIES IN ITALY

Journal: Eur Rev Med Pharmacol Sci. 2016 Dec;20(1 Suppl):7-10.

Gardini I, Bartoli M, Conforti M, Mennini FS, Marcellusi A, Lanati EP

HCV - TREATMENT RATIO AND GOVERNANCE FOOTPRINTS: ANALYSIS OF REGIONAL DIFFERENTIATION IN ITALY

Journal: Eur Rev Med Pharmacol Sci. 2016 Dec;20(1 Suppl):4-6.

Lanati EP, Marcelli A

ITALIAN TIMINGS IN NEW DRUGS APPROVAL: AN UP-TO-DATE ANALYSIS

Journal: Value Health. 2016 Nov;19(7):A448, Poster PHP 49. Wien, ISPOR 19th European Congress 2016

Lanati EP, Lidonnici D, Ronco V

ABSENCE OF PRICE-PREVALENCE CORRELATION IN ORPHAN DRUGS IN ITALY

Journal: Value Health. 2016 Nov;19(7):A600, Poster PSY 141. Wien, ISPOR 19th European Congress 2016

Lanati EP, Lidonnici D, Ronco V

ASSESSMENT OF REGIONAL LEGISLATION RELATED TO THE USE OF SIMILAR BIOLOGICAL MEDICINAL PRODUCTS: THE ITALIAN CASE STUDY

Journal: Value Health. 2016 Nov;19(7):A450, Poster PHP 62. Wien, ISPOR 19th European Congress 2016

Iorio A, Lanati EP

HCV: ESTIMATION OF THE NUMBER OF DIAGNOSED PATIENTS ELIGIBLE TO NEW ANTI-HCV THERAPIES IN ITALY

Journal: Value Health. 2016 Nov;19(7):A450, Poster PGI 7. Wien, ISPOR 19th European Congress 2016

Gardini I, Bartoli M, Conforti M, Mennini FS, Marcellusi A, Lanati EP

HCV: TREAT RATIO AND GOVERNANCE FOOTPRINTS. ANALYSIS OF REGIONAL DIFFERENCES IN ITALY

Journal: Value Health. 2016 Nov;19(7):A515, Poster PGI 33. Wien, ISPOR 19th European Congress 2016

Lanati EP, Pizzi A, Marcelli A

BUDGET IMPACT ANALYSIS OF TRIVERAM FOR THE TREATMENT OF HYPERTENSION IN ITALY

Journal: Value Health. 2016 Nov;19(7):A643, Poster PCV 41. Wien, ISPOR 19th European Congress 2016

Lanati EP, Orlando VL, Doratori S

BUDGET IMPACT ANALYSIS OF COSYREL FOR THE TREATMENT OF HYPERTENSION IN ITALY

Journal: Value Health. 2016 Nov;19(7):A643, Poster PCV 38. Wien, ISPOR 19th European Congress 2016

Lanati EP, Orlando VL, Doratori S

BUDGET IMPACT ANALYSIS OF VIACORAM FOR THE TREATMENT OF HYPERTENSION IN ITALY

Journal: Value Health. 2016 Nov;19(7):A644, Poster PCV 44. Wien, ISPOR 19th European Congress 2016

Lanati EP, Orlando VL, Doratori S

2015

ETHICAL ASSESSMENT OF HEPATITIS C VIRUS TREATMENT: THE LESSON FROM FIRST GENERATION PROTEASE INHIBITORS

Journal: Dig Liver Dis. 2015 May;47(5):351-5

Sacchini D, Craxì L, Refolo P, Minacori R, Cicchetti A, Gasbarrini A, Cammà C, Spagnolo AG; WEF Study Group

ECONOMIC ASSESSMENT OF ELTROMBOPAG IN THE TREATMENT OF THROMBOCYTOPENIA

Journal: Expert Review of Pharmacoeconomics & Outcomes Research, 2015;15(4):713-20

Romano F, Ruggeri M, Coretti S, Giannini EG, Sacchini D, Annicchiarico BE, Marchetti M, Rodeghiero F, Lidonnici D

ADAPTING THE ADPKD OUTCOMES MODEL TO PREDICT COST CONSEQUENCE IN ITALIAN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) TREATED WITH JINARC (TOLVAPTAN)

Journal: Value Health. 2015 Nov;18(7):A755, Poster PND 39. Milan, ISPOR 18th European Congress 2015

Mennini FS, Marcellusi A, Russo S, Iorio A, Lanati EP, Robinson P

PROTON PUMP INHIBITORS IN ITALY: IT’S TIME TO MAKE A (POLICY) CHANGE

Journal: Value Health. 2015 Nov;18(7):A632, Poster PGI 54. Milan, ISPOR 18th European Congress 2015

Lidonnici D, Lanati EP

NUTRITIONAL ASPECTS AND DISINFORMATION IN LIVER DISEASE: A QUESTIONNAIRE-BASED SURVEY IN ITALIAN PATIENTS

Journal: Value Health. 2015 Nov;18(7):A630-1, Poster PGI 47. Milan, ISPOR 18th European Congress 2015

Gardini I, Lanati EP, Caporaso N, Fontana R, Lidonnici D

BUDGET IMPACT ANALYSIS OF TRIPLIAM FOR THE TREATMENT OF HYPERTENSION IN ITALY

Journal: Value Health. 2015 Nov;18(7):A384, Poster PCV 61. Milan, ISPOR 18th European Congress 2015

Lanati EP, Orlando VL

ECONOMIC ASSESSMENT OF ELTROMBOPAG IN THE TREATMENT OF THROMBOCYTOPENIA

Journal: Value Health. 2015 Nov;18(7):A626, Poster PGI 22. Milan, ISPOR 18th European Congress 2015

Romano F, Ruggeri M, Coretti S, Giannini EG, Sacchini D, Annicchiarico BE, Marchetti M, Rodeghiero F, Lidonnici D

2014

EXPERT OPINION OF NEPHROLOGISTS ABOUT THE EFFECTIVENESS OF LOW-PROTEIN DIET IN DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE (CKD)

Journal: International Journal of Food Sciences and Nutrition. September 2014, Volume 29, pp 1-6

Trifirò G, Fatuzzo PM, Ientile V, Pizzimenti V, Ferrajolo C, Santoro D, Camacho N, Van Rosmalen J, D'Addetta G, Lanati EP, Caputi AP, Catinello G, Savica V

ECONOMIC EVALUATION OF AGOMELATINE FOR MAJOR DEPRESSIVE DISORDERS RELATIVE TO OTHER ANTIDEPRESSANTS IN THE ITALIAN SETTING

Journal: Value Health. 2014 Nov;17(7):A460, Poster PMH 36. Amsterdam, ISPOR 17th European Congress 2014

Lanati EP, Lidonnici D

PATIENTS DIAGNOSTIC THERAPEUTIC PATHWAYS FOR HCV PATIENTS IN ITALY: IMPACT OF REGIONALIZATION IN TREATMENTS AND GUIDELINES  

Journal: Value Health. 2014 Nov;17(7):A372, Poster PGI 55. Amsterdam, ISPOR 17th European Congress 2014

Lanati EP, Lidonnici D, Gasbarrini A, Ruggeri M, Sacchini D, Caporaso N, Fagiuoli S

COHORT OF HCV PATIENTS IN ITALY: SIZING AND TREATMENTS IN A SAMPLE OF ITALIAN HEPATOLOGY CENTERS

Journal: Value Health. 2014 Nov;17(7):A371, Poster PGI 47. Amsterdam, ISPOR 17th European Congress 2014

Lanati EP, Lidonnici D, Gasbarrini A, Ruggeri M, Sacchini D, Caporaso N, Fagiuoli S

2013

I QUADERNI DI MEDICINA IL SOLE24ORE SANITA’ – LUGLIO 2013

Journal: Terzo Workshop di Economia e Farmaci in Epatologia - WEF-E 2013

Cicchetti A, Gasbarrini A, Ruggeri, M, Romano F, Cammà C, Marchetti M, Carletto A, Sacchini D, Refolo P, Minacori R, Carosi G, Caraceni P, Taliani G, Fagiuoli S, Lucà MG, Magini G, De Giorgio M, Oleari F, Gardini I, Giannini EG, Raimondo G, Saitta C, Toniutto P, Farinati F, Castelli G, Cabibbo G, Turriziani A, Grieco A, Biolato M, Spagnolo AG

I QUADERNI DI MEDICINA IL SOLE24ORE SANITA’ – GIUGNO 2013

Journal: Primo Workshop di Economia e Farmaci per le Malattie Infiammatorie Croniche Intestinali - WEF-IBD 2013

Cicchetti A, Gasbarrini A, D’Incà R, Caporaso N, Musto D, Nardone OM, Armuzzi A, Orlando A, Blandizzi C, Castiglione F, Testa A, Annese V, Danese S, Ruggeri, M, Romano F, Cappello M, Cammà C, Bravatà I, Marchetti M, Carletto A, Sacchini D, Refolo P, Minacori R, Canarecci S, Greco M, Leone S

CROHN’S DISEASE: AN ECONOMIC ASSESSMENT OF BIOLOGICAL DRUGS IN ITALY

Journal: Value Health. 2013 Nov;16(7):A497–A498, Poster PGI 29. Dublin, ISPOR 16th European Congress 2013

Cicchetti A, Gasbarrini A, Ruggeri M, on behalf of WEF study group

HOW THE PRICING STRATEGY OF 2ND GENERATION HCV DIRECT ANTIVIRAL AGENTS CAN AFFECT THE NUMBER OF TREATED PATIENTS IN ITALY AND THE NATIONAL DRUG BUDGET

Journal: Value Health. 2013 Nov;16(7):A501, Poster PGI 47. Dublino, ISPOR 16th European Congress 2013

Lanati EP,Lidonnici D, Cammà C and the WEF study group

HEPATOCELLUL AR CARCINOMA: AN EPIDEMIOLOGICAL AND MANAGEMENT SURVEY-BASED ANALYSIS IN ITALY

Journal: Value Health. 2013 Nov;16(7):A494, Poster PGI 8. Dublin, ISPOR 16th European Congress 2013

Cicchetti A, Gasbarrini A, Ruggeri M, Sacchini D, on behalf of WEF study group

WORKSHOP IN PHARMACOECONOMICS: AN ITALIAN EXPERIENCE OF MULTI-STAKEHOLDER HTA CONSENSUS

Journal: Value Health. 2013 Nov;16(7):A479–A480, Poster PHP 159. Dublin, ISPOR 16th European Congress 2013

Cicchetti A, Gasbarrini A, Ruggeri M, Sacchini D, Lanati EP

2012

VALUTAZIONE ECONOMICA DI UN PROGRAMMA DI SCREENING ANTI-HCV IN ITALIA

Journal: Pharmacoeconomics – Italian Research Articles. July 2011, Volume 13, Issue 2, pp 81-99

Cicchetti A, Ruggeri M, Coretti S, Piscaglia A, Ponziani FR, Lanati EP e Gasbarrini A

NEW ANTIVIRAL DRUGS FOR HEPATITIS C IN ITALY: WILL IT BE A TREASURE HUNT?

Journal: Value Health. 2012 Nov;15(7):A331–A332, Poster PGI 32. Berlino, ISPOR 15th European Congress 2012

Gardini I, Fontana R, Fumagalli M, Conforti M, Lanati EP

2011

SCAN: AN INTEGRATED SYSTEM FOR MARKET ACCESS OF NEW DRUGS IN ITALY

Journal: Value Health. 2011 Nov;14(7):A425, Poster PRM 24. Madrid, ISPOR 14th European Congress 2011

Lanati EP, D’ausilio A, Lidonnici D, Iorio A, Jommi C

LA DIETA IPOPROTEICA NELLA GESTIONE DEL PAZIENTE NEFROPATICO IN CAMPANIA: UN’ANALISI DI IMPATTO DI BUDGET

Poster 4° Congresso Nazionale SIHTA 2011

D’Ausilio A, Lanati EP, Quintaliani G

Ufficio di Milano e sede legale:
Via Vincenzo Monti, 3 - 20123 Milano
T +39 02 89096682
F +39 02 89098927
P.I/C.F. 07135170962 REA: MI-1938 161
Mail info@maprovider.com
PEC maprovider@legalmail.it

Fatturazione Elettronica
SDI USAL8PV
PEC fatture.maprovider@pec.it

Ufficio di Roma:
Piazza di San Salvatore in Lauro 10 - 00186 Roma
T +39 06 68806614
F +39 06 68806614

Credits

Privacy Policy

Copyright 2020 MA Provider